Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
People sometimes overlook how much work goes into developing something as commonplace in pharmaceuticals as Polyacrylic Resin Ⅱ. Its story pulls from decades of chemistry innovation, starting with the initial syntheses of acrylic polymers in the mid-1900s. Back then, researchers wanted replacements for natural gums and found polyacrylates promised stability, clarity, and resistance to acids. Over time, tweaks in production processes and purification brought about grades that meet the runs of different pharmacopeias: BP, EP, and USP. These distinctions carry weight in the pharmaceutical industry, as manufacturers must source excipients that match strict consistency and impurity standards from regulators in different parts of the world. Polyacrylic Resin Ⅱ became a vital toolkit item for formulators after improvements in polymerization technology allowed for better control over molecular weight, crosslinking, and functional group modification.
Most drugmakers and suppliers know Polyacrylic Resin Ⅱ by more than one moniker—carbomer, carboxypolymethylene, or simply acrylic acid polymer. Each title harks back to the chemical backbone: long chains built from acrylic acid subunits, dotted with carboxyl groups that give these powders their powerful water-absorbing nature. This class of material stands out because it swells to hundreds of times its mass in water, forming clear gels with ease. In tablets, creams, and suspensions, Polyacrylic Resin Ⅱ serves as thickener, binder, and controlled release agent, matching the expectations set by pharmacopeia requirements.
Anyone who handles Polyacrylic Resin Ⅱ daily knows it doesn’t act like your average polymer. Most forms arrive as white, fluffy powders that drift at the slightest breath of air. Sprinkle some into water and you see the transformation: slow hydration, followed by significant swelling, then rapid thickening as the structure entangles with itself and the surrounding water. That’s all down to the density of carboxyl groups along the chain, which don’t just welcome water—they also snag onto calcium ions and other salts, changing the polymer’s thixotropy and viscosity. Most analytic tests land the molecular weight in the millions, often over 3 million g/mol, with tight limits on residual monomer and organic impurities per pharmacopeial monographs. Even slight tweaks to the polymer backbone can change how well it performs in a delivery system, making these variables more than trivia for formulators.
Pharma work leaves no room for error, and Polyacrylic Resin Ⅱ brings a long checklist. If you read any certificate of analysis, it lists appearance, loss on drying, pH in dispersion, heavy metal content, and transmittance, among many other specs. Each property tracks risks—from microbial growth to contaminant carryover—that can affect patient safety. Regulators set these bars high: permissible limits for heavy metals rest in the 10 ppm range; loss on drying rarely breaks 2%; pH stays around neutral if you disperse it in water. Packaging tells its own story: pharmaceutical grade resins show clear batch tracing, expiry dates, and handling instructions for GMP compliance. All these steps grew out of lessons learned over decades in real production environments, not from bureaucratic theory.
People might imagine polymerization as a matter of mixing chemicals and waiting. On the shop floor, it turns into a careful balancing act. Producers mix acrylic acid derivatives with initiators in strictly controlled environments, as runaway polymerization can mean safety hazards and off-spec batches. Oxygen, temperature, and purity controls all matter, since even a trace of unwanted ions can mess up the reaction kinetics. Once the wet polymer forms, manufacturers dry, mill, and purify the powder. Crosslinking agents like allyl ethers tie the matrix together, affecting how much water it can grab later on. Years of scale-up experiments showed which conditions yielded a product that met the pharmaceutical-grade expectations every time, with minimal batch-to-batch drift.
Polyacrylic Resin Ⅱ doesn’t stay idle in formulation labs. Chemists learned to tinker with its structure to give it new functions. The most common reaction is crosslinking, which ties separate polymer chains together at various points—this boosts gel strength and adjusts release properties for oral and topical drugs. Quaternization brings cationic features to the table, making the polymer less sensitive to counterion presence in fluids like stomach acid. Some labs graft side chains to improve biocompatibility or make the polymer respond to certain triggers, like pH or temperature swings. All these chemical tweaks target a purpose: either making medicines last longer in the body, reducing irritation, or shortening the manufacturing steps for complex drugs.
Drug makers and suppliers see a confusing array of names when searching for Polyacrylic Resin Ⅱ. For regulatory filings, the common global words include Carbomer, Acrylic acid polymer, Carboxyvinyl polymer, and Carboxypolymethylene. Some suppliers use their own brand codes or molecular weight identifiers, which can hide key differences to the untrained eye. Every synonym carries weight in customs, importation, and quality checks, meaning missing a detail can stall a shipment or trigger an audit. The language around this material evolved out of practical problem-solving, not jargon for its own sake.
Polyacrylic Resin Ⅱ doesn’t enjoy the luxury of “generally recognized as safe” in every setting. Manufacturing plants and labs must treat it with respect: airborne dust can irritate lungs and eyes, while leftover monomers or impurities can cause skin reactive episodes. Real-world safety means strong filtration, personal protective equipment, and diligent cleaning routines after each batch. Storage standards remain strict—tightly sealed, away from moisture, at stable temperatures. Over the years, incidents have shown where shortcuts can spark fires, dust explosions, or hazardous waste. Investing in safety programs—regular training, proper documentation, and rig consistent to Good Manufacturing Practice—tends to save far more trouble than it costs.
I’ve watched Polyacrylic Resin Ⅱ anchor many advances in drug delivery and topical formulations. In oral tablets, it acts as both a binder and a sustained release matrix, allowing active ingredients to seep out slowly in the body—essential for therapies requiring steady-state bloodstream levels. Creams and gels take advantage of its thickening power with low dosing, giving products a smooth, stable feel that patients will actually use. Eye drops, oral suspensions, and even wound care products draw on this polymer to keep APIs suspended evenly, resist microbial contamination, or deliver drugs at a fixed rate. As more companies look for non-animal derived excipients, Polyacrylic Resin Ⅱ’s synthetic origin makes it a go-to for vegan, kosher, or halal products.
Research teams keep pushing Polyacrylic Resin Ⅱ into new territory. A lot of the current focus sits with smart drug delivery: adjusting the polymer to tune release profiles further, target drug delivery deep into tissues, or respond to environmental cues in the body. Efforts show up in making combined polymers—blends of Polyacrylic Resin Ⅱ with cyclodextrins or polysaccharides offer improved solubilization of poorly soluble drugs, which has long been a sticking point in oral formulations. Field data keep coming in on patient acceptability, allergenic potential, and bioadhesion—a sign that the material is still evolving, with plenty of practical questions to solve.
No excipient gets a free pass without safety evidence. Polyacrylic Resin Ⅱ underwent plenty of toxicological testing over the years: oral, dermal, and ocular administration in animals as well as long-term exposure models. Data so far support low absorption from the GI tract, meaning the polymer stays largely in the gut when swallowed, with minimal systemic risk if the finished product contains only pharma grade material. Local irritation, mainly with repeated skin or eye exposure, remains the main concern, which points regulators and manufacturers to favor rinsing and protective measures rather than seeking new animal studies. Heavy scrutiny falls on any production side-product or modification, since even a single stray contaminant can upend large-scale production clearance. Labs and regulators keep pressure up to spot subtle toxicity cases that might only show up after years of real-world use.
Future prospects rest on ongoing need for safer, more controllable, and patient-friendly medicines. Personalized medicine, where every patient’s drug might come in a slightly adjusted tablet or gel, asks for excipients that handle complex drug combinations, low batch volumes, and nontraditional manufacturing methods like 3D printing. Polyacrylic Resin Ⅱ already figures close to the front of this curve, thanks to its predictable structure, adaptability, and long safety track record in pharma. Few materials offer the same blend of performance, cross-compatibility, and non-biologic origin. Big questions remain around environmental impact and recyclability, as more governments and public health watchers turn their focus to pharmaceutical pollution. It’s on manufacturers, regulators, and researchers to make these next chapters safe, sustainable, and open to new medical breakthroughs.
Every pill you see on pharmacy shelves carries more than its intended medication. Take Polyacrylic Resin Ⅱ BP EP USP Pharma Grade. It doesn’t grab headlines, but it keeps each tablet solid and predictable. As a pharmaceutical excipient, this resin brings better control over how drugs release in the body. A lot of long-acting and enteric-coated tablets depend on it, allowing doctors to fine-tune timing so a patient’s experience is smoother and safer.
The reality of many medicines: some need to slide past the stomach before breaking down. Gut acid is tough—too tough for certain active ingredients. Tablets coated with Polyacrylic Resin Ⅱ handle that challenge with ease. They travel through the stomach, then break apart further along the digestive tract. That’s crucial for medications intended to target the intestines or for those that irritate the stomach lining. Without this type of enteric coating, some effective treatments would cause side effects or never reach their target area at all.
People stick with their prescriptions when they’re easier to take. Polyacrylic Resin Ⅱ plays a big role in extended-release (ER) drug products. Instead of flooding the body with a full dose at once—which might cause spikes and crashes—pills formulated with this resin let the medicine seep out slowly. Lower peaks and fewer dips can mean fewer side effects, better symptom management, and less risk for those with sensitive bodies.
Chewable tablets and dispersible powders aren’t known for great flavor. Polyacrylic Resin Ⅱ helps mask unpleasant tastes by building a protective layer around the active particles. Kids and adults who dread the bitterness of some medications have an easier time sticking with their regimen. That thin coat does double duty: it keeps moisture out and stretches out shelf life, something any pharmacist appreciates when dealing with sensitive compounds.
Manufacturers often wrestle with variable humidity, ingredient instability, and strict regulations. Polyacrylic Resin Ⅱ shines thanks to its chemical stability and its track record with BP, EP, and USP standards. Consistency matters in healthcare. No one wants to find their prescription weaker simply because the weather shifted during storage. This resin forms a reliable seal, giving peace of mind to both the companies that make the drugs and the patients that use them.
Unnecessary additives clog up some pills and bring about sensitivity issues in patients with allergies. By focusing on excipients like Polyacrylic Resin Ⅱ, pharmaceutical scientists cut back on extra fillers without losing functional performance. Streamlining how tablets hold together and dissolve builds in an extra layer of safety, plus makes unit-dose packaging a lot easier for busy clinics and hospitals.
The market always pushes for faster production, longer shelf life, and fewer patient complaints. Polyacrylic Resin Ⅱ is part of that equation, picking up the slack where older ingredients fall short. Ongoing research could unlock plant-based alternatives for those who want an even greener supply chain. Still, in my time working alongside healthcare professionals, I keep seeing the same lesson: reliability saves everyone—from the maker down to the person taking a daily pill.
Polyacrylic Resin Ⅱ, especially with the tags BP, EP, and USP, pops up on ingredient lists for a reason: it's a binder and sometimes a coating. Tablets stick together because of it, and drug formulas rely on it to deliver active ingredients at the right pace in the body. I keep a close eye on any new chemical in pharmaceuticals, especially polymers. You find plenty of synthetic materials in pills and powders today, but not all shine under a safety spotlight.
Our trust in medicine comes from proven standards. BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) didn't slap their labels on Polyacrylic Resin Ⅱ after a chat over coffee. Long-term studies matter here. Regulatory scrutiny means researchers have checked the resin for purity, possible contamination, toxic byproducts, and what happens after you swallow it. In short, the resin can't mix in anything harmful or break down into anything unsafe during storage or metabolism.
Digging into the science journals and reports shows that polyacrylic resins have held up to the microscope fairly well. They don't show off as allergens, and their breakdown products pass safely through the digestive system in most cases. Still, as someone who's dealt with patients experiencing rare side effects, I know every polymer deserves repeat reviews as manufacturing changes or new suppliers enter the market. Not all batches are created equal. Trace contaminants—think solvents, metals, or monomers—pose a bigger threat than the polymer itself. Pharmaceutical-grade resins go through intensive checks to filter these out, but it feels risky to claim absolute safety for all users, especially the very young or those with compromised digestion.
Watching strict quality control in action gives some reassurance. Pharma companies run resin batches through identity checks and impurity profiling far beyond supermarket-level testing. Published studies often focus on chronic exposure, since medicines tend to be taken for weeks or months, not just once. Animal toxicity studies and human clinical trials both check for inflammation, buildup in organs, or any cancer concerns. Reports to regulators don't stop after launch—adverse events trigger immediate review, and manufacturing can shift course fast to solve any problem.
Reducing risk always feels possible. Pushing for more detailed public reporting on supplier audits and trace contaminant results would help. Some lower-income markets may not police suppliers as closely, so sharing testing protocols and results globally might cut risks for everyone. Pharma companies can also fund follow-up studies on special patient groups—children, kidney patients, allergy-prone folks—who may react differently, and then update information for prescribers.
Patients shouldn't ignore ingredient lists. Asking about inactive ingredients isn't just for folks with allergies. If a provider recommends a medication with polyacrylic resin, ask about brand differences—generic drugs sometimes use different sources. Bulk purchasing through reputable pharmacies, especially those following European or North American standards, cuts the chance of subquality materials. Healthcare providers can report suspected intolerance or adverse effects, even rare ones, to national monitoring programs. Each report strengthens the knowledge base for everyone.
Polyacrylic Resin Ⅱ, when made and tested to BP, EP, and USP standards, checks out for most people. Mistakes or shortcuts in the supply chain, though, can undo that track record in a hurry. The safest path means open records, active surveillance, and an informed public—and that can only strengthen trust in the pills and capsules that keep people healthy.
Polyacrylic Resin Ⅱ holds a special spot in the pharmaceutical world. Every pharmacist, warehouse manager, or logistic worker who deals with pharmaceutical excipients knows that a single mistake can put product safety and patient health at risk. You learn quickly that what seems like "just another powder" demands deep respect for established rules. The consequences for cutting corners range from regulatory warnings to medication recalls or, worse yet, harming patients who trust every pill they swallow.
For Polyacrylic Resin Ⅱ, moisture is more enemy than friend. Even brief exposure to humidity can mess up its consistency and alter how it behaves in a formulation. I've seen first-hand how careless warehouse design—like a busted HVAC or blocked airflow—lets dampness creep in, and bags start clumping or caking. Once that happens, batch rejections or complaints soon follow. Keeping temperature tightly within 15–25°C and humidity below 50% makes a difference.
Leaving resin anywhere near water, cleaning stations, or open windows guarantees trouble. Supervisors who set up simple visual checks for leaks and temperature spikes prevent a lot of headaches. Some facilities add humidity loggers in storage rooms. These low-cost devices offer proof of compliance, which smooths things over if an auditor pops in unexpectedly.
The bags holding pharmaceutical-grade polyacrylic resin aren't your weak grocery store plastic. They're multi-layered, often with an inner liner to keep moisture out and an outer shell that stands up to tears and abrasions. Everyone handling these materials must resist the urge to drag or drop them. Manual handling gone wrong leads to punctures, and resins escaping containment are more than just wasted product—they’re a contamination risk.
Once you open a bag, there’s a small clock ticking. Unused resin shouldn’t linger in half-closed sacks. Resealing tightly with tamper-proof ties and clear labeling stamps out mix-ups. In every plant I've visited, having clean scoops and tools—set aside just for this raw material—cuts down on cross-contamination.
Pharmaceutical audits don’t focus only on paperwork. Inspectors want to see that every Polyacrylic Resin II lot gets tracked from the dock to the blending line. I remember a time when manufacturers used scribbled labels and handheld spreadsheets; mistakes slipped through. Digital inventory and batch tracking systems now help maintain full traceability. Should a problem happen, the quality team can pull the exact lot from the market without shutting down the entire product line.
Regulators expect to see Standard Operating Procedures (SOPs) for storage and handling—these aren’t just thick binders on a shelf. They must match everyday reality. Training sessions, refreshers, and spot checks keep the rules clear and front-of-mind for staff at every level.
Most problems with polyacrylic resin come down to small lapses—a door left open, a torn bag ignored, sloppy record-keeping. Taking the time to store it in the right place, protected from moisture, and handling each batch with care, prevents the most common headaches.
For companies serious about pharmaceutical safety and regulatory compliance, these routines form the backbone of quality. They may sound basic, but lives depend on pharmaceutical workers doing things right every single day. The stakes are real, and attention to detail is never wasted.
Polyacrylic Resin Ⅱ finds steady use in a range of pharmaceutical settings, from controlled-release coatings to taste-masking ingredients. Anyone working in a production plant or a compounding lab recognizes why shelf life matters. Misjudging expiry dates can push costs up, and in the context of medicines, patient safety depends on trustworthy materials.
In my own experience with pharmaceutical supply chains, the way a material gets handled matters as much as the original shelf life figure. Polyacrylic Resin Ⅱ, under the designation BP EP USP, usually shows a shelf life of about three years if kept in unopened, original containers and protected from moisture, heat, and sunlight. Quality control teams often point to 25°C as the upper limit for long-term storage, since higher temperatures speed up the breakdown of resins and let in unwanted moisture.
Manufacturers base the three-year guideline on stability data—real tests where technicians store the material and check performance over time. According to published regulatory guidelines, such as those from the European Pharmacopoeia and United States Pharmacopeia, even small increases in ambient humidity can shorten usable life. Keeping Polyacrylic Resin sealed, dry, and cool doesn’t just preserve physical properties—these steps help prevent downstream processing problems in tablet production or liquid suspensions.
Expired excipients may cause formulation headaches. I once saw a batch of tablets fail disintegration tests because the coating polymer had absorbed too much moisture during a hot summer. Those tablets went straight to scrap—thousands of dollars lost to poor storage. In regulated environments, using resin that has gone beyond its recommended shelf life can trigger compliance violations and, for outsourced solid dosage forms, lead to recalls.
With active pharmaceutical ingredients, people talk a lot about pharmacological potency. Excipients like Polyacrylic Resin don’t get the same level of public attention, but they still affect whether the medicine works as expected or falls apart before reaching the patient. By sticking to shelf life dates, labs and manufacturers protect their process reliability.
Some companies treat shelf life as just a box to check on the logistics spreadsheet. Working directly with pharmacists and production staff, I’ve noticed the biggest improvements come from practical steps—double-sealing open containers with desiccants, writing open dates directly on drums, keeping inventory rotated so oldest stock gets used first. Staff training around storage and documentation helps teams catch mistakes before they turn into batch failures.
Quality assurance isn’t just paperwork. It means regular checks for clumping, color changes, or shifts in particle size. If the resin no longer pours easily, or the granules start sticking together, those are early warning signs. Labs can test suspect lots using infrared or chromatographic methods to measure degradation products. Investing time to spot these problems early easily outweighs the costs of failed batches or product recalls.
Global regulators agree that pharmaceuticals rely on more than just pure actives. Excipients like Polyacrylic Resin need careful management of shelf life to ensure every tablet, capsule, or suspension performs consistently. Reliable potency starts with a stable supply chain, practical storage, and teams that take label dates seriously. That’s not just best practice—it keeps companies profitable and patients safe.
Polyacrylic resin Ⅱ, found on so many excipient labels, has become a staple in controlled-release tablets, pellets, and oral suspensions. Used for film coating and drug delivery, this polymer earns its place through a unique mix of swelling ability and water solubility. Its role feels simple on the surface but mixing it with other excipients often complicates things. Each batch can turn into uncharted territory, especially if someone takes compatibility for granted.
Pharmaceuticals don’t leave room for trial and error, at least not in commercial manufacturing. If you think about the day's work in a formulation lab, you only feel at ease once you’ve checked how your resin behaves with common tablet disintegrants, fillers, binders, lubricants, and even flavors.
Direct mixing of polyacrylic resin Ⅱ with alkaline materials like magnesium stearate can cause issues. The basic environment threatens the polymer's stability, risking changes in drug release. On the other end, strong acids can spark hydrolysis, reducing shelf life and reliability. If someone combines this resin carelessly with water-soluble sugars—mannitol or lactose, for example—hygroscopicity may rise, making tablets break down or stick together during storage.
Colorants and preservatives often come laced with sodium compounds, which can alter pH and even disrupt polymer hydration. This seems minor until you notice blisters, softening, or unexpected dissolution in the warehouse. Interactions with anionic surfactants deserve special attention, as these can cause the resin to clump or fail when forming films. Wet granulation, a go-to process, brings more pitfalls: too much water and the resin over-hydrates, leading to pasty masses unfit for compression.
A while back, I worked on a generic sustained-release tablet that relied on this resin for its release matrix. Early batches looked fine in the lab, but issues popped up after adding sodium lauryl sulfate into the mix for better wetting. The coating began showing fine cracks and the tablets peeled in stability trials. Reading the research later, I learned the obvious reason: anionic surfactants weaken the resin's structure by breaking its ionic bonds. It’s humbling to see the science play out right on your benchtop and in the rejected batch records.
The key step starts with small-scale compatibility tests. Pair the resin with your proposed excipients and accelerate the conditions—heat, humidity, and light—to see what fails. Solid-state NMR and HPLC aren’t just expensive toys; they spot early-stage breakdown before you run into regulatory headaches. Every time you introduce a new filler or flavoring, don’t skip stress stability studies, even when results feel predictable.
Adjusting your formulation rarely means starting over. Sometimes, selecting neutral fillers or switching to non-ionic surfactants solves the problem outright. If the resin reacts, tweaking pH with a buffer or using a moisture-proof coating layer preserves performance. Most companies rely on published data, but my own caution comes from witnessing costly recalls due to overlooked incompatibilities.
A successful pharmaceutical product rarely hides surprises; its invisibility in the marketplace comes from trusted, predictable performance. Polyacrylic resin Ⅱ brings lots to the table, but only when you know the risks that come from pairing it with just any excipient. A few hours spent understanding true interaction—salt, sugar, or surfactant—save months of troubleshooting and keep patients safe. The real lesson: don’t treat compatibility as a checklist, but as an ongoing responsibility in drug development.
| Names | |
| Preferred IUPAC name | Poly(1-carboxyethylene) |
| Other names |
Acrylic Resin Polyacrylic Acid Resin Carbomer Polymethylacrylate Acrylic Polymer |
| Pronunciation | /ˌpɒli.əˈkrɪl.ɪk ˈriː.zɪn ˈtuː ˌbiːˈpiː ˌiːˈpiː ˌjuːˈɛsˈpiː ˈfɑːr.mə ɡreɪd/ |
| Identifiers | |
| CAS Number | 9003-01-4 |
| Beilstein Reference | 1312993 |
| ChEBI | CHEBI:53487 |
| ChEMBL | CHEMBL1201471 |
| ChemSpider | 23542621 |
| DrugBank | DB09414 |
| ECHA InfoCard | ECHA InfoCard: 100.115.258 |
| EC Number | 9003-01-4 |
| Gmelin Reference | 40387 |
| KEGG | C13418597 |
| MeSH | D020061 |
| PubChem CID | 71392553 |
| RTECS number | VZ4050000 |
| UNII | 4A6I18C1AY |
| UN number | UN1866 |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product 'Polyacrylic Resin Ⅱ BP EP USP Pharma Grade' is "DTXSID2020815 |
| Properties | |
| Chemical formula | (C3H4O2)n |
| Molar mass | No data |
| Appearance | White or almost white powder |
| Odor | Odorless |
| Density | 1.20 g/cm3 |
| Solubility in water | Insoluble |
| Acidity (pKa) | 5.5 – 7.5 |
| Basicity (pKb) | 7.5 (pKb) |
| Refractive index (nD) | 1.48 |
| Viscosity | 800-1200 mPa.s |
| Dipole moment | 1.82 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 114.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | A01AB11 |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause skin and eye irritation. Dust may form explosive mixtures with air. |
| GHS labelling | GHS07, Exclamation Mark |
| Pictograms | GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | > 250°C |
| Autoignition temperature | > 400°C |
| LD50 (median dose) | > 2,000 mg/kg (rat, oral) |
| NIOSH | Not established |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.06 mg/kg |
| Related compounds | |
| Related compounds |
Polyacrylic Acid Carbomer Acrylic acid Polymethyl methacrylate Methacrylic acid Polyvinyl alcohol |
Chengguan District, Lanzhou, Gansu, China
